Augmedics Valuation, Funding & Investors
Augmedics is valued at $33M as of September 2017.
Last Augmedics valuation
$33M
Series A · Sep 2017
Last Augmedics funding round
$83M
Series D · Jun 2023
Cumulative funding Augmedics raised
$144M
across 6 funding rounds
Key investors in Augmedics
XR Invest
H.I.G. Capital
Almeda Ventures
Revival Healthcare Capital
TerraLab Ventures
Israel Innovation Authority
About Augmedics
Augmedics is a Chicago-headquartered medical device company developing augmented reality guidance for spine surgery. Its flagship xvision Spine System projects 3D CT images onto the patient's anatomy in real time through a surgeon-worn AR headset, enhancing precision during pedicle screw placement. Cleared by the FDA in 2021, the technology supports minimally invasive procedures at hospitals across the United States and Europe.
Founded
2014
HQ
Chicago, ILWebsite
Status
Privately held
Customer focus
B2B
Revenue model
Product sales
Valuation
$33M (Sep 2017)
Augmedics Valuation
Augmedics is currently valued at $33M, based on its Series A in September 2017.
The $8M round was led by XR Invest, with participation from Terra Funda and Israel Innovation Authority.
Augmedics valuation by funding round
| Date | Stage | Valuation |
|---|---|---|
| Sep 2017 | Series A | $33M |
Augmedics Funding History
Augmedics has raised a total of $144M across 6 funding rounds.
Augmedics' first fundraising round was a $1M seed round in January 2015. The most recent completed round was a $83M Series D in June 2023.
Augmedics funding rounds
| Date | Stage | Investors | Raised | Valuation | Deal Summary |
|---|---|---|---|---|---|
| Jun 2023 | Series D | CPMG (lead); Evidity Health Capital (lead); Revival Healthcare Capital; H.I.G. Capital; Almeda Ventures | $83M | - | Augmedics, a Chicago-based pioneer in augmented reality (AR) surgical navigation, specializes in the xvision Spine System, which provides surgeons with 'x-ray vision' to accurately navigate instruments and implants during spine procedures. Founded in 2014 with R&D in Israel and headquartered in Illinois, the company received FDA 510(k) clearance for its technology and had treated at least 4,000 US patients as of June 2023. On June 27, 2023, Augmedics closed an $82.5 million Series D funding round led by CPMG and Evidity Health Capital, with participation from existing investors H.I.G. Capital, Revival Healthcare Capital, Almeda Ventures, and others. This brought total funding to approximately $143-148 million across seven rounds. CPMG's Kent McGaughy and Evidity's Paul Enever joined the board. The proceeds will support expansion of Augmedics' US commercial footprint and development of next-generation platform advancements to drive mass adoption of xvision technology amid a competitive enabling surgical tech landscape. The round's success in a challenging fundraising environment highlights investor confidence in Augmedics' clinical impact and leadership in AR spine surgery. No financial metrics such as post-money valuation, revenue, ARR, EBITDA, or valuation multiples were disclosed in connection with this round. A prior valuation of $33.18 million was noted from September 2017, but no current figures were available. |
| Mar 2021 | Series C | Almeda Ventures (lead); H.I.G. Capital (lead); Revival Healthcare Capital (lead); HCA Healthcare; XR Invest | $36M | - | Augmedics develops xvision Spine, an augmented reality surgical image guidance system that provides surgeons with 'x-ray vision' during spinal procedures, enhancing accuracy without external distractions. The company launched commercial sales in the U.S. in the second half of 2020 and performed over 250 spinal surgeries by year-end despite the COVID-19 pandemic. On March 30, 2021, Augmedics raised $36 million in an oversubscribed Series C round led by H.I.G. Capital, Revival Healthcare Capital, and Almeda Ventures, with participation from other investors including HCA Healthcare, bringing total funding to $63 million at that time. The proceeds support U.S. and international commercialization, next-generation product development, expansion to new indications, and CE certification for Europe. The round highlights strong demand for Augmedics' technology, as evidenced by rapid sales growth in a challenging year, positioning the company as a leader in AR for complex surgeries like spine operations, which number around 8 million annually globally. Investors praised the integration of breakthrough AR into surgical workflows and the experienced leadership team. This funded platform expansion using AR and AI for spinal surgery navigation. Augmedics continued growth with over 10,000 AR spine surgeries completed by April 2025, a U.S. commercial launch of CT-Fluoro registration for broader navigation access, and acquisitions of digital health assets from bankrupt Surgalign and Holo Surgical to strengthen its AR/AI portfolio. The company has raised approximately $149-196 million total across multiple rounds, focusing on musculoskeletal and potential cranial applications. |
| Jun 2020 | Series B | AUG Management (lead); XR Invest; TerraLab Ventures | $15M | - | Augmedics raised $15 million in its Series B funding round on June 15, 2020, led by its U.S. employees through AUG Management LLC, which invested $4 million amid COVID-19 challenges when traditional VC support fell away. XR Invest participated as an existing investor. The funding enabled the commercial launch of the xvision Spine System, an augmented reality surgical image guidance platform for spine surgeries. The company had received FDA approval in December 2019 and began U.S. sales in the second half of 2020 despite pandemic disruptions to elective surgeries. |
| Sep 2017 | Series A | XR Invest (lead); Terra Funda; Israel Innovation Authority | $8M | $33M | Augmedics raised an $8.3 million Series A round on September 18, 2017, led by XR Invest with participation from Israel Innovation Authority and Terra Funda. The post-money valuation was $33.18 million. This followed a Series Seed round of $1 million in January 2015. Augmedics develops augmented reality surgical image guidance technology, pioneering solutions like xvision Spine for spinal surgeries. The company began U.S. sales of xvision Spine in the second half of 2020, completing over 250 spinal surgeries that year. Subsequent rounds included a $15 million Series B in June 2020, $36 million Series C in March 2021 led by H.I.G. Capital, Revival Healthcare Capital, and Almeda Ventures, and an $82.5 million Series D in June 2023, bringing total funding to over $143 million. |
| Jul 2015 | Seed | TerraLab Ventures (lead); BizTEC | $800K | - | - |
| Jan 2015 | Seed | Terra Venture Partners | $1M | - | - |
Who has invested in Augmedics?
13 investors have backed Augmedics across its funding rounds, including XR Invest, H.I.G. Capital, Almeda Ventures, Revival Healthcare Capital, TerraLab Ventures and Israel Innovation Authority.
Lead investors include CPMG, Evidity Health Capital, Almeda Ventures, H.I.G. Capital, Revival Healthcare Capital and 3 other investors.
Augmedics Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
 Zug | 3 | Lead | Sep 2017 | |
| United States | 2 | Lead | Mar 2021 | |
| Miami, FL | 2 | Lead | Mar 2021 | |
 Tel Aviv | 2 | Lead | Mar 2021 | |
| Nazareth Illit | 2 | Lead | Jul 2015 | |
| Nashville, TN | 1 | Participant | Mar 2021 | |
| Jerusalem | 1 | Participant | Jan 2015 | |
| -- | 1 | Participant | Sep 2017 | |
| New York City, NY | 1 | Lead | Jun 2023 | |
![](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 20 20"><rect fill="%23e5e7eb" width="20" height="20" rx="4"/></svg>){kind=small} AUG Management | Chicago, IL | 1 | Lead | Jun 2020 |
| Dallas, TX | 1 | Lead | Jun 2023 | |
This data is available for Pro users. Sign up to see all 13 Augmedics investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAugmedics Competitors
Augmedics competitors include listed companies like Carclo and Abingdon Health, and private ones like Bridge Therapeutics, Enspire DBS Therapy, Inner Cosmos and Navigantis.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| United States | Private | - | - | $33M | - | |
| Cleveland, OH | Private | - | - | $33M | - | |
| San Francisco, CA | Private | - | - | $33M | - | |
| Miami, FL | Private | - | - | $33M | - | |
 United Kingdom | Publicly listed | $153M | $25M | $35M | 0.4x | |
| United Kingdom | Publicly listed | $11M | ($4M) | $36M | 2.1x |
Augmedics Public Comps
Augmedics is still privately-owned, but its public comps include Nortech Systems, Ortoma, Diagnostic Medical Systems, Baird Medical Investment, HeraMED, iTonic Holdings, Mauna Kea Technologies, Q-linea, xReality Group and InspireMD.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $118M | $2M | 0.4x | - | 22.0x | - | |||
| $7M | ($481K) | 4.0x | 3.8x | (54.7x) | (10.3x) | |||
| $58M | $4M | 0.9x | 0.9x | 14.7x | 8.5x | |||
| Baird Medical Investment | $23M | ($25M) | 2.1x | - | (1.9x) | - | ||
| $209K | ($3M) | 151.9x | - | (11.2x) | - | |||
| $523K | ($5M) | 63.4x | - | (6.5x) | - | |||
| $9M | ($9M) | 4.5x | 4.7x | (4.7x) | (10.8x) | |||
| $1M | ($16M) | 14.8x | - | (1.0x) | - | |||
This data is available for Pro users. Sign up to see all Augmedics competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Augmedics
| When was Augmedics founded? | Augmedics was founded in 2014. |
| Where is Augmedics headquartered? | Augmedics is headquartered in Chicago, IL, United States. |
| Is Augmedics publicly listed? | No, Augmedics is a private, VC-backed company. |
| What is Augmedics' valuation? | Augmedics was last valued at $33M in its Series A in September 2017. |
| How much funding has Augmedics raised? | Augmedics has raised $144M across 6 funding rounds. |
| What was Augmedics' last funding round? | Augmedics' last funding round was a $83M Series D in June 2023, led by CPMG and Evidity Health Capital. |
| Who are Augmedics' investors? | Augmedics' investors include XR Invest, Revival Healthcare Capital, H.I.G. Capital, Almeda Ventures, TerraLab Ventures, HCA Healthcare, Terra Venture Partners, Terra Funda, Evidity Health Capital, AUG Management and 3 others. |
| Which companies are comparable to Augmedics? | Companies comparable to Augmedics include Bridge Therapeutics, Enspire DBS Therapy, Inner Cosmos, Navigantis, Carclo and Abingdon Health. |
See companies similar to Augmedics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.